Specac Limited has announced that Shannon Postma has been appointed as its new Managing Director. Shannon joins the business as the previous MD, David Smith, assumes the new role of Commercial Director. David will remain on the Board of Directors and will focus his effort on driving commercial success in new application areas including in the diagnostics, analytics and life sciences markets.
Shannon is an Australian national who has led, grown and sold businesses with attributes similar to Specac. He was most recently General Manager of The Galloway Group, a diversified group of Australian SMEs and is an experienced commercial and operational leader; both being focus areas for Specac over the next five years as it becomes a larger, more sophisticated business.
Commenting on his appointment, Shannon says “The entire team at Specac have every right to be proud of what they have achieved and the foundations they have built for a very exciting future. I am delighted to be joining this team and with Foresight Group's on-going support I am looking forward to Specac’s journey in delivering its next stage of growth.”
Chris Wardle, Investor Director representing Specac investor Foresight Group added, “David and the team have done a fantastic job to get Specac to where it is today, with the business more than doubled in size since our investment. As we look to scale the business rapidly, Shannon’s experience in building efficient sales teams and operational excellence will be key to our success. A significant growth area for spectroscopy is the life sciences market and David’s focus here will no doubt yield great results for the group. We’d like to thank David for his contributions to date and are excited to continue to work together.”
David Smith says, “This is an historic day for Specac, and I’m delighted that we’ve made such progress as a team that we can attract an MD of the calibre of Shannon. I have no doubt he will help us to improve enormously as a business.”
